Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rita Nogueiras-Álvarez has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medication adherence in clinical trials: measurement methods, methodological challenges, and reporting standards

    by Rita Nogueiras-Álvarez, Rossana Roncato, Mirjana Stanić Benić, Sanita Maleškić Kapo, Ines Potočnjak, Andrej Belančić

    1. Medication adherence is a major determinant of therapeutic efficacy and effectiveness and one of the most important yet insufficiently controlled variables in clinical research. Across chronic a...

  • Pharmacogenetics in HIV therapy: a review of key biomarkers, regulatory annotations, and clinical dosing guidelines

    by Rita Nogueiras-Álvarez

    1. In 1987, zidovudine (AZT) became the first drug approved for the treatment of human immunodeficiency virus (HIV) infection.Its mechanism of action was based on inhibiting viral replication in in...

  • Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance

    by Rita Nogueiras-Álvarez, Montserrat García García, Urko Aguirre Larracoechea

    • 14 October 2026
      • Vol. 82  (11)

    Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance.

    by Rita Nogueiras-Álvarez, Montserrat García García, Urko Aguirre Larracoechea

    Pharmacovigilance aims to ensure that the risk-benefit balance remains favourable throughout the entire life-cycle of drugs. Although JAK inhibitors have been associated with the development of skin cancers, melanoma is not mentioned in their data sheets, except in the case of tofacitinib. A case/non-case study was performed in EudraVigilance to evaluate the association between exposure to JAK inhibitors and the adverse reaction "skin melanomas(excluded ocular)" by calculating the reporting odds ratio. Additionally, univariate and multivariate analysis were performed to assess whether different variables could have an influence on melanoma development. Until April 30, 2025, the EudraVigilance database included 158 reports with tofacitinib, 65 with ruxolitinib, 42 with upadacitinib, 21 with baricitinib, 2 with filgotinib, and 1 with abrocitinib. The reporting odds ratio analysis showed a signal between exposure to baricitinib, ruxolitinib, tofacitinib, upadacitinib, and the explored adverse reaction. Besides, when analysing the association of malignant melanoma (the most frequently coded PT in individual case reports) with different variables, a statistically significant association was observed based on the drug(p = 0.0014) and the indication(p = 0.0037). In this EudraVigilance disproportionality analysis, signals of disproportionate reporting for cutaneous melanoma were identified for baricitinib, ruxolitinib, tofacitinib, and upadacitinib. These findings are hypothesis-generating and should not be interpreted as evidence of a causal association. Further evaluation in cohort studies, disease registries, and electronic health-record databases is required to confirm and quantify any potential association between JAK inhibitor exposure and melanoma. Given the seriousness of melanoma and the potential influence of confounding and surveillance bias, these results support maintaining clinical vigilance and appropriate dermatological monitoring in patients receiving JAK inhibitors, particularly those with additional melanoma risk factors.

  • Impact of Tacrolimus Intra‐Patient Variability on Toxicity Development Among Lung Transplant Recipients

    by Rita Nogueiras‐Álvarez, Víctor Manuel Mora‐Cuesta, José Manuel Cifrián‐Martínez, María del Mar García‐Saiz

    Immunosuppressive treatment helps to reduce the risk of rejection after transplantation. However, it is important to be aware of the potential toxicities that can develop after this therapy initiation. Tacrolimus is currently the calcineurin inhibitor of choice in the post‐transplantation immunosuppressive therapy, and its intra‐patient variability (Tac‐IPV) has been proposed in recent years as a useful biomarker in post‐transplant outcomes. We performed an observational retrospective study in 195 lung transplant recipients to determine the potential impact of Tac‐IPV as a biomarker in the development of cardiovascular toxicities and renal impairment in the post‐transplantation evolution. Different Tac‐IPV calculation measurements were shown to be statistically associated with the development of arterial hypertension de novo in the univariate analysis: the standard deviation ( p = 0.016 for tacrolimus C min values; p = 0.022 for tacrolimus dose‐adjusted values); the coefficient of variation ( p = 0.021 for C min ; p = 0.031 for dose‐adjusted values); and the mean absolute deviation (MAD) ( p = 0.043 for C min ; p = 0.033 for dose‐adjusted values). Those patients with a MAD ≥ 16.47% had a higher risk of renal impairment ( p = 0.045). In our study, different Tac‐IPV measures were associated with arterial hypertension in lung transplantation follow‐up. Patients with a high Tac‐IPV, using the MAD as a measurement, showed a higher risk for renal impairment. No other statistically significant associations were found for the other studied events.

  • Tacrolimus Intrapatient Variability as a Biomarker in Solid Organ Transplantation

    by Rita Nogueiras‐Álvarez, María del Mar García‐Saiz

    Tacrolimus is the primary calcineurin inhibitor agent prescribed in different solid organ transplantation modalities. Among its characteristics, tacrolimus has a high inter‐ and intrapatient variability. Recently, tacrolimus intrapatient variability (Tac‐IPV) has been proposed as a useful biomarker to predict outcomes in different types of solid organ transplantation. This work includes a systematic review of the literature that evaluates Tac‐IPV influence on solid organ transplantation outcomes from inception to September 18, 2024. Although there are several publications assessing the influence of Tac‐IPV in transplantation, we found that there is a lack of consensus regarding which is the best measure to evaluate Tac‐IPV. Moreover, the ideal post‐transplantation period for evaluating this biomarker has not been established so far. Different cut‐off points have been proposed, especially in adult kidney transplantation, where most of the studies have been carried out, but these cut‐off values may not be applicable to other transplantation modalities. This work includes a description of the main findings of different studies in an attempt to state what the current knowledge on the topic is in different solid organ transplantation modalities.


  • Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy

    by Rita Nogueiras‐Álvarez, Inés Pérez Francisco

    With the continuous development of genetics in healthcare, there has been a significant contribution to the development of precision medicine, which is ultimately aimed at improving the care of patients. Generally, drug treatments used in Oncology are characterized by a narrow therapeutic range and by their potential toxicity. Knowledge of pharmacogenomics and pharmacogenetics can be very useful in the area of Oncology, as they constitute additional tools that can help to individualize patients' treatment. This work includes a description of some genes that have been revealed to be useful in the field of Oncology, as they play a role in drug prescription and in the prediction of treatment response.


  • Open Access

    Off-Label Immunosuppressant Drugs in Solid Organ Transplantation

    by Rita Nogueiras-Álvarez, María del Mar García-Sáiz

    Once a solid organ transplantation (SOT) has been performed, it is necessary to prescribe immunosuppressant medication to prevent graft rejection. This task has the peculiarity that many of these drugs do not have specific indications for transplant use in the technical data sheets. We performed a review of different immunosuppressive drugs’ information available at European and American regulatory agencies in order to analyze the approved indications by the type of SOT. In our work, besides showing these differences between different indication approvals in different SOT modalities, we also attempted to reflect other differences under the approved indications according to age group, formulation type, geographical area, etc. Although consensus documents on the subject have been published, the access to immunosuppressants depends on each country’s regulation and healthcare system, and off-label prescription is a reality that healthcare professionals need to be familiar with.


  • Open Access

    Pharmacogenomics in clinical trials: an overview

    by Rita Nogueiras-Álvarez

    With the trend towards promoting personalised medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the purposes of clinical trials, the inclusion of PGx is an additional tool that should be considered for improving our knowledge about the effectiveness and safety of new drugs. A search of available clinical trials containing pharmacogenetic and PGx information was conducted on ClinicalTrials.gov. The results show there has been an increase in the number of trials containing PGx information since the 2000 s, with particular relevance in the areas of Oncology (28.43%) and Mental Health (10.66%). Most of the clinical trials focus on treatment as their primary purpose. In those clinical trials entries where the specific genes considered for study are detailed, the most frequently explored genes are CYP2D6 (especially in Mental Health and Pain), CYP2C9 (in Hematology), CYP2C19 (in Cardiology and Mental Health) and ABCB1 and CYP3A5 (particularly prominent in Transplantation and Cardiology), among others. Researchers and clinicans should be trained in pharmacogenetics and PGx in order to be able to make a proper interpretation of this data, contributing to better prescribing decisions and an improvement in patients’ care, which would lead to the performance of PM.


  • Open Access

    Calcineurin inhibitors’ impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain

    by Rita Nogueiras-Álvarez, Víctor Manuel Mora-Cuesta, José Manuel Cifrián-Martínez, María Ángeles de Cos-Cossío, María del Mar García-Sáiz

    Patients undergoing lung transplantation (LTx) need administration of immunosuppressive therapy following the procedure to prevent graft rejection. However, these drugs are not exempt from potential risks. The development of cardiovascular risk factors and impaired renal function in the post-transplantation period are conditions that may be favoured by the use of calcineurin inhibitor (CNI) drugs which could have repercussions on the quality of life and the post-transplantation evolution. To evaluate the cardiovascular and renal toxicity following the administration of CNI as maintenance immunosuppression in lung transplant recipients (LTRs) we reviewed a total number of 165 patients undergoing LTx between 01/01/2015 and 08/12/2018. They were divided into two groups according to the CNI drug administrated: cyclosporine (CsA-group) with 11 patients or tacrolimus (Tac-group), with 154 patients. We evaluated the de novo occurrence of arterial hypertension (HTN), diabetes mellitus (DM), hyperlipidemia and impaired renal function after initiation of CNI administration. In addition to that, the time until each of these events was assessed. A higher rate for developing HTN (p < 0.001) and impaired renal function (p = 0.047) was observed within the CsA-group. The new onset of hyperlipidemia was similar between both CNI groups and de novo appearance of DM was only documented in those LTRs receiving tacrolimus. In this LTRs retrospective study, it was observed that having ≥ 4 tacrolimus trough levels above the upper limit of the proposed interval for each specific post-LTx period was associated with an increased risk for developing renal impairment. No other statistically significant association was found between supratherapeutic CNIs blood levels and the evaluated toxicities.